Furthermore, Guanabenz shows potential in elevating parkin levels to combat neurodegeneration [69], and Topiramate paired with GABRB1 may help manage levodopa-induced dyskinesia [71]. The gene discussed is PRKN; the disease is drug-induced dyskinesia.